Tratamiento con ciclosporina al 0.1% (Ikervis(R)) en conjuntivitis corticodependiente asociada a dupilumab / Cyclosporine 0.1% (Ikervis(R)) treatment in steroid-dependent dupilumab-associated conjunctivitis
Arch. Soc. Esp. Oftalmol
; 94(8): 396-399, ago. 2019. ilus
Article
in Spanish
| IBECS
| ID: ibc-185626
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
El dupilumab es un fármaco de reciente aprobación por la Food and Drug Administration (FDA) y la European Medical Agency (EMA) para el tratamiento de la dermatitis atópica moderada-severa en adultos. El incremento de la frecuencia de conjuntivitis asociadas a dupilumab ha sido expuesto en publicaciones y ensayos recientes. Presentamos 2 casos de conjuntivitis corticodependiente tratados satisfactoriamente con ciclosporina al 0,1% (Ikervis(R)). No hay casos previos descritos de conjuntivitis asociada a dupilumab tratados con ciclosporina al 0,1% (Ikervis(R))
ABSTRACT
Dupilumab is a drug that has recently been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for the treatment of moderate-to-severe atopic dermatitis in adults. An increase in frequency of conjunctivitis related to dupilumab treatment has been reported in recent publications and clinical trials. We report two steroid-dependent cases satisfactorily treated with cyclosporine 0.1% (Ikervis(R)). To our knowledge there are no reported cases of dupilumab-associated conjunctivitis treated with cyclosporine 0.1% (Ikervis(R)
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Cyclosporine
/
Conjunctivitis
/
Dermatitis, Atopic
/
Antibodies, Monoclonal, Humanized
/
Immunosuppressive Agents
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Arch. Soc. Esp. Oftalmol
Year:
2019
Document type:
Article
Institution/Affiliation country:
Hospital Universitari i Politecnic La Fe/España